Does a high arachidonic acid to EPA (AA:EPA) ratio indicate a pro-inflammatory and pro-thrombotic state?

The arachidonic acid to eicosapentaenoic acid (AA:EPA) ratio is an established biomarker that reflects the metabolic competition between these two fatty acids for enzyme-mediated conversion into signaling molecules. Because both fatty acids utilize the same enzymatic machinery, the ratio of their availability determines whether a patient’s internal environment favors pro-inflammatory or anti-inflammatory pathways.

Mechanistic basis of lipid-mediator balance

AA and EPA compete for access to cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. When the ratio is high, AA dominates the enzymatic active sites, leading to the preferential synthesis of 2-series prostaglandins (such as PGE2) and 4-series leukotrienes.

• Pathway bias: These AA-derived mediators are potent drivers of inflammatory signaling and vascular constriction.
• Competitive inhibition: Increasing EPA levels (lowering the ratio) allows EPA to competitively inhibit AA metabolism. EPA is converted into 3-series eicosanoids and specialized pro-resolving mediators (SPMs) that possess significantly lower inflammatory potency or actively resolve existing inflammation.

Clinical evidence for inflammation and thrombosis

A high AA:EPA ratio is strongly associated with biomarkers of systemic inflammation and increased cardiovascular risk factors.

• Inflammatory markers: Clinical studies demonstrate that high ratios correlate with elevated levels of high-sensitivity C-reactive protein (hs-CRP) and Interleukin-6 (IL-6). In aging populations, higher EPA levels relative to AA are specifically linked to reduced subclinical inflammation.
• Thrombotic potential: High AA levels drive the production of Thromboxane A2 (TXA2), a powerful platelet aggregator and vasoconstrictor. EPA competes for this pathway to produce TXA3, which has minimal pro-thrombotic activity.
• Cardiovascular outcomes: Research indicates that a high AA:EPA ratio is a significant predictor of acute coronary syndrome and major adverse cardiovascular events (MACE). Conversely, lowering this ratio through supplementation has been shown to reduce platelet hyperactivity and stabilize atherosclerotic plaques.

Bottom line

A high AA:EPA ratio is a scientifically supported indicator of a pro-inflammatory and pro-thrombotic state. It reflects a biochemical bias where arachidonic acid-derived mediators dominate, increasing the risk for systemic inflammation and cardiovascular complications through enhanced platelet activation and elevated inflammatory signaling.